Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG reports news on a late-stage ophthalmology and neuro-ophthalmology pipeline focused on eye and optic-nerve disorders with unmet medical need. Company updates commonly cover OCS-01 eye drops for diabetic macular edema, Privosegtor for optic neuritis and other optic neuropathies, and Licaminlimab, a topical anti-TNFα candidate being developed for dry eye disease with a genotype-based approach.
Recurring developments include clinical-program updates, FDA and EMA regulatory interactions, scientific meeting presentations, pipeline reviews, financial results, capital-market communications, annual general meeting materials, and notifications of managerial transactions. Oculis is a Swiss biopharmaceutical company with ordinary shares traded on Nasdaq and Nasdaq Iceland under OCS.
Oculis (NASDAQ: OCS) presented DME AWARE Delphi findings at ARVO 2026 highlighting unmet needs in diabetic macular edema (DME).
Experts prioritized non-invasive therapies and early intervention; consensus favored treating early-stage DME with an eye drop. Oculis expects topline DIAMOND Phase 3 results for OCS-01 in June 2026.
Oculis (Nasdaq: OCS) will present clinical and corporate updates at Eyecelerator and ARVO 2026, May 1–6, 2026. Presentations cover DIAMOND Phase 3 (OCS-01 eye drops) with topline results expected June 2026, DME AWARE Delphi Study findings on unmet needs in DME, and Phase 2 ACUITY post‑hoc OCT analyses for Privosegtor.
Sessions include a company update May 1, DME AWARE results May 4, and Privosegtor neuroprotective data May 6; recent regulatory designations and registrational programs are also highlighted.
Oculis (Nasdaq: OCS) published its invitation to the 2026 Annual General Meeting, to be held May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, with in-person attendance and a broadcast (no virtual participation).
Shareholders on Nasdaq US will receive physical proxy materials; Nasdaq Iceland shareholders may submit electronic voting instructions via the Lumi AGM platform. A shareholder information session with management is scheduled for May 11, 2026 in Reykjavík and via webcast; meeting materials and replays are available on the investor website.
Oculis (Nasdaq: OCS) completed the last patient visit in its two Phase 3 DIAMOND trials for OCS-01 eye drops in diabetic macular edema (total >800 patients). Topline results are expected in June 2026, with a potential NDA submission in Q4 2026.
Both 52-week, randomized, double-masked registrational trials follow positive Stage 1 findings showing visual acuity gains and rapid edema reduction; OCS-01 targets a U.S. market estimated at $3 billion.
Oculis (NASDAQ:OCS) announced the vesting and settlement of previously granted restricted stock units (RSUs) to a company director. The notification names Riad Sherif and cites an RSU vesting/settlement event dated 5 April 2026.
The disclosure is a routine insider transaction notice about equity compensation processing.
Oculis (Nasdaq: OCS) announced management will participate in investor conferences in April 2026, including a company presentation at the Needham Healthcare Conference on April 14, 9:30 AM ET, and one-on-one meetings at Van Lanschot Kempen Life Sciences Conference on April 15-16.
The company highlighted upcoming pivotal readouts: OCS-01 DIAMOND Phase 3 topline results due June 2026, Licaminlimab PREDICT-1 topline planned late 2026, and Privosegtor holding FDA Breakthrough and EMA PRIME designations for optic neuritis.
Oculis (Nasdaq: OCS) announced that Privosegtor received EMA PRIME designation for optic neuritis on March 31, 2026, following a January 2026 FDA Breakthrough Therapy designation and existing Orphan Drug status from both EMA and FDA.
EMA support reflects positive Phase 2 ACUITY visual, anatomical and biological results; Oculis is advancing the global PIONEER registrational program, with PIONEER-1 initiated in Q4 2025.
Oculis (NASDAQ:OCS) on March 27, 2026 announced annual equity incentive awards granted to a member of its executive committee.
The notification covers an executive equity award and accompanies an attached manager-transaction notice dated March 2026.
Oculis (Nasdaq: OCS) will present Phase 2 ACUITY results for Privosegtor at NANOS 2026 on March 23, 2026, highlighting improved low‑contrast visual acuity and neuroprotective structural and biological effects in acute optic neuritis.
The company noted FDA Breakthrough Therapy designation for optic neuritis and said it initiated the PIONEER registrational program, with PIONEER‑1 started in Q4 2025.
Oculis (OCS) announced notifications of ordinary share purchases by a member of its Board of Directors.
The company attached transaction notices dated March 12, 2026 and March 13, 2026, naming board member Christina Ackermann.